Squarepoint
NVCT icon

Squarepoint’s Nuvectis Pharma NVCT Stock Holding History

Squarepoint’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$403K Buy
+19,095
New +$403K ﹤0.01% 3543
2025
Q2 		– Sell
-11,012
Closed -$108K – 4877
2025
Q1 		$108K Sell
11,012
-8,059
-42% -$58K ﹤0.01% 4199
2024
Q4 		$103K Buy
+19,071
New +$119K ﹤0.01% 4689

Other funds holding NVCT

Iridian Asset Management
Iridian Asset Management Westport, Connecticut $275M AUM 37.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Baldwin Wealth Partners
Baldwin Wealth Partners Marion, Massachusetts $1.52B AUM 21.45% 1-Year Est. Return
Oppenheimer & Co
Oppenheimer & Co New York $9.5B AUM 27.65% 1-Year Est. Return
J.M. Forbes & Co
J.M. Forbes & Co Boston, Massachusetts $1.33B AUM 21.14% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
Austin Wealth Management
Austin Wealth Management Austin, Texas $477M AUM 11.7% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return

Squarepoint's NVCT Position: Q3 2026 in Review

Squarepoint opened a new position in Nuvectis Pharma (NVCT) in Q3 2026: 19,095 shares worth $403K. The stake represents ﹤0.01% of the portfolio and ranks #3543 among its holdings. This is a return to the name: Squarepoint previously reported a position in NVCT as recently as Q1 2025.

Squarepoint first reported a position in NVCT in Q4 2024 and has held it in 3 quarters since. 33 funds tracked by Wall St. Rank hold NVCT as of Q3 2026.

  • Squarepoint held 19,095 shares of Nuvectis Pharma worth $403K as of Q3 2026.
  • Nuvectis Pharma was a new Squarepoint position in Q3 2026.
  • Nuvectis Pharma made up ﹤0.01% of Squarepoint's portfolio in Q3 2026, its #3543 holding.
  • Squarepoint first reported a position in Nuvectis Pharma in Q4 2024 and has held it in 3 quarters since.
  • 33 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.